Local Glucocorticoids in Treatment of Children with Dermatitis

Local glucocorticoids (GCs) are the gold standard of anti-inflammatory topical therapy. The description of the main pharmaceutics properties and classification of local GCs, as well as its indications and contradictions are presented in the article. This article also provides fundamentals for application of local GCs which should be implemented for effective and safe use of these drugs in children. The problems of steroid-phobia (one of the reasons of the wrong and untimely administration of local GCs) are discussed. Advantages of 0.1% methylprednisolone aceponate (new generation GCs) use are discussed. This medication has optimal efficiency/safety ratio and unique bioactivation pathway that enables its effective administration in management of various dermatitis in children from 4 months of age. Results of different comparative and double blind placebo-controlled clinical trials of 0.1% methylprednisolone aceponate administration are discussed in this article. High efficiency and safety of this medication are noted. The use of modern local GCs at the first signs of skin inflammatory changes allows to relieve aggravation quickly and achieve remission of the disease.

1. Blume-Peytavi U, Wahn U. Optimizing the treatment of atopic dermatitis in children: a review of the benefit/risk ratio of methylprednisolone aceponate. J Eur Acad Dermatol Venereol. 2011;25(5):508-515. doi: 10.1111/j.1468-3083.2010.03942.x.

2. Ruzicka T. Methylprednisolone aceponate in eczema and other inflammatory skin disorders — a clinical update. Int J Clin Pract. 2006;60(1):85-92. doi: 10.1111/j.1368-5031.2005.00754.x.

3. Klinicheskie rekomendatsii «Seboreynyy dermatit u detey» [Internet]. Moscow: Soyuz pediatrov Rossii; 2016. (In Russ). Доступно по: https:// kiberis.ru/?p=50254. Ссылка активна на 12.06.2019.

4. Macharadze DS, Tsintsadze NN. Solar urticaria and other photodermatosis. Meditsinskiy sovet. 2011; (5-6):30-34. (In Russ).

5. Levina YuG, Alekseeva AA, Vishneva EA, et al. The role of topical glucocorticosteroid methylprednisolone aceponate in external therapy of atopic dermatitis in children. Pediatric pharmacology. 2017;14(6):520-526. (In Russ). doi: 10.15690/pf.v14i6.1836.

6. Allergologija i immunologija dlja pediatrov (Klinicheskie rekomendatsii dlya pediatrov). Ed by AA Baranov, RM Haitov. 3th ed. revised and updated. Moscow: Sojuz pediatrov Rossii; 2011. 256 р. (In Russ).

7. Miller JA, Munro DD. Topical Corticosteroids: clinical pharmacology and therapeutic use. Drugs. 1980;19(2):119-134. doi: 10.2165/00003495-198019020-00004.

8. Soyuz pediatrov Rossii; Rossiyskaya assotsiatsiya allergologov i klinicheskikh immunologov; Rossiyskoye obshchestvo dermatoven-erologov i kosmetologov. Klinicheskiye rekomendatsii «Atopicheskiy dermatit u detey» [Internet]. Moscow; 2016. (In Russ). Доступно по: http://www.pediatr-russia.ru/sites/default/files/file/kr_ad.pdf. Ссылка активна на 12.06.2019.

9. Allergiya u detej: ot teorii — k praktike. Series: Sovremennaja pediatrija: ot teorii — k praktike. Ed by LS Namazova-Baranova. Moscow: Soyuz pediatrov Rossii; 2010-2011. 668 p. (In Russ).

10. Namazova-Baranova LS, Baranov AA, Kubanova AA, et al. Atopic Dermatitis in children: current clinical guidelines for diagnosis and therapy. Current Pediatrics. 2016;15(3):279-294. (In Russ). doi: 10.15690/vsp.v15i3.1566.

11. European Dermatology Forum. EDF-Guidelines for Treatment of Atopic Eczema (Atopic Dermatitis). Part I [cited 2018 January 24]. Available from: http://www.turkderm.org.tr/turkdermData/Uploads/files/EDF-guideline-Atopic-Eczema-update%202018.pdf.

12. Batyrshina SV. Glucocorticoids for topical application in the modern treatment of inflammatory dermatoses in pediatric practice. Practical medicine. 2014;(9):94-102. (In Russ).

13. Levina YuG, Alekseeva AA, Vishneva EA, et al. Peculiarities of external therapy of atopic dermatitis in children: role of methylpredni-solone aceponate. Pediatric pharmacology. 2014;11(5):52-58. (In Russ). doi: 10.15690/pf.v11i5.1165.

14. Lomonosov KM, Ignat'yev DV. Topicheskiye steroidy v lechenii dermatozov s vyrazhennym giperkeratozom. Consilium medicum. Dermatology. 2009;(2):3-8. (In Russ).

15. Volkova EN, Lange DA, Rodina luA, Tarasova MV. The use of methylprednisolone aceponate in the combined treatment of chronic dermatoses: analysis of erroneous applications. Klinicheskaya dermatologiya i venerologiya. 2010;8(5): 97-102. (In Russ).

16. Luger TA. Balancing efficacy and safety in the management of atopic dermatitis: the role of methylprednisolone ace-ponate. J Eur Acad Dermatol Venereol. 2011;25(3):251-258. doi: 10.1111/j.1468-3083.2010.03789.x.

17. Muller SM, Tomaschett D, Euler S, et al. Topical corticosteroid concerns in dermatological outpatients: a cross-sectional and interventional study. Dermatology. 2016;232(4):444-452. doi: 10.1159/000446068.

18. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116-132. doi: 10.1016/j.jaad.2014.03.023.

19. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol. 2000; 142(5):931-936. doi: 10.1046/j.1365-2133.2000.03473.x.

20. Beattie PE, Lewis-Jones MS. Parental knowledge of topical therapies in the treatment of childhood atopic dermatitis. Clin Exp Dermatol. 2003;28(5):549-553. doi: 10.1046/j.1365-2230.2003.01357.x.

21. Cork MJ, Britton J, Butler L, et al. Comparison of parent knowledge, therapy utilization and severity of atopic eczema before and after explanation and demonstration of topical therapies by a specialist dermatology nurse. Br J Dermatol. 2003;149(3): 582-589. doi: 10.1046/j.1365-2133.2003.05595.x.

22. Lee JY, Her Y, Kim CW, Kim SS. Topical corticosteroid phobia among parents of children with atopic eczema in Korea. Ann Dermatol. 2015;27(5):499-506. doi: 10.5021/ad.2015.27.5.499.

23. Gelmetti C, Wollenberg A. Atopic dermatitis — all you can do from the outside. Br J Dermatol. 2014;170 Suppl 1:19-24. doi: 10.1111/bjd.12957.

24. Long CC, Mills C, Finlay AY. A practical guide to topical therapy in children. Br J Dermatol. 1998;138(2):293-296. doi: 10.1046/j.1365-2133.1998.02077.x.

25. Bewley A. Changing the way we advise patients on use of topical steroids. Prescriber. 2009;20(7):42-48. doi: 10.1002/psb.495.

26. Korotky NG, Taganov AV, Shimanovsky NL. Experience of Advantan usage in treatment of pediatric atopic dermatitis. Pediatria. Zhurnal imeni G.N. Speranskogo. 2000;79(5):18. (In Russ).

27. Torrelo A. Methylprednisolone aceponate for atopic dermatitis. Int J Dermatol. 2017;56(6):691-697. doi: 10.1111/ijd.13485.

28. Luger TA, Loske KD, Elsner P et al. [Topical skin therapy with glucocorticoids — therapeutic index. (In German).] J Dtsch Dermatol Ges. 2004; 2(7):629-634. doi: 10.1046/j.1439-0353.2004.03626.x.

29. Garcia Ponte L, Ebert U. Frontiers of rapid itch relief: a review of methylprednisolone aceponate. J Eur Acad Dermatol Venereol. 2012;26 Suppl 6:9-13. doi: 10.1111/j.1468-3083.2012.04711.x.

30. Meffert H, Schuppler J. Methylprednisolone aceponate lotion for treatment of acute eczema. Zeitschrift fur Hautkrankheiten. 1999;74:88-94.

31. Haria M, Balfour JA. Methylprednisolone aceponate. A review of its pharmacological properties and therapeutic potential in the topical treatment of eczema. Clin Immunother. 1995;3(3): 241-253. doi: 10.1007/bf03259059.

32. Osnovy klinicheskoy immunologii i allergologii: uch. posobiye. Ed. by LS Namazova-Baranova, LV Gankovskaya, RYa Meshkova. Moscow: Pediatr”; 2016. 152 р. (In Russ).

33. Belousova TA. The external therapy of allergic dermatitis and eczema. Vestnik dermatologii i venerologii. 2008;(2):97-103. (In Russ).

34. Bieber T, Vick K, Folster-Holst R, et al. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy. 2007;62(2):184-189. doi: 10.1111/j.1398-9995.2006.01269.x.

35. Proksch E, Foelster-Holst R, Jensen JM. Skin barrier function, epidermal proliferation and differentiation in eczema. J Dermatol Sci. 2006;43(3):159-169. doi: 10.1016/j.jderms-ci.2006.06.003.

36. Mirshahpanah P, Docke WD, Merbold U, et al. Superior nuclear receptor selectivity and therapeutic index of methylprednisolone aceponate versus mometasone furoate. Exp Dermatol. 2007;16(9):753-761. doi: 10.1111/j.1600-0625.2007.00597.x.

37. Romaniuk FP. Pediatrician's view on the treatment of atopic dermatitis with methylprednisolone. Medical Council. 2019;(17):208-216. (In Russ).